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Abstract
Background: Regulated intramembrane proteolysis of the β-amyloid precursor protein by the γ-
secretase yields two peptides. One, amyloid-β, is the major component of the amyloid plaques
found in Alzheimer's disease patients. The other, APP IntraCellular Domain, has been involved in
regulation of apoptosis, calcium flux and gene transcription. To date, a few potential target genes
transcriptionally controlled by AID, alone or complexed with Fe65/Tip60, have been described.
Although the reports are controversial: these include KAI1, Neprilysin, p53, EGFR, LRP and APP itself.
Furthermore, p53 has been implicated in AID mediated susceptibility to apoptosis. To extend these
findings, and assess their in vivo relevance, we have analyzed the expression of the putative target
genes and of the total brain basal transriptoma in transgenic mice expressing AID in the forebrain.
Also, we have studied the susceptibility of primary neurons from such mice to stress and pro-
apoptotic agents.
Results: We found that AID-target genes and the mouse brain basal transcriptoma are not
influenced by transgenic expression of AID alone, in the absence of Fe65 over-expression. Also,
experiments conducted on primary neurons from AID transgenic mice, suggest a role for AID in
sensitizing these cells to toxic stimuli. Overall, these findings hint that a role for AID, in regulating
gene transcription, could be induced by yet undefined, and possibly stressful, stimuli in vivo.
Conclusion: Overall, these data suggest that the release of the APP intracellular domain may
modulate the sensitivity of neuronal cells to toxic stimuli, and that a transcriptional role of AID
could be inscribed in signaling pathways thatare not activated in basal conditions.
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Processing of Amyloid Precursor Protein (APP) by β- and
γ-secretase produces Aβ peptides and APP IntraCellular
Domain [1,2], the former being the major component of
AD amyloid plaques. Recent evidence indicates that AID
is a biologically active intracellular peptide. Initial find-
ings indicated that AID could sensitize cells to apoptotic
stimuli [3]. Subsequent studies have suggested a role of
AID in calcium release from endoplasmic reticulum stores
[4]and in gene transcription [5]. The putative transcrip-
tional role of AID has attracted most of the attention
because of the functional parallel with Notch signaling,
another γ-secretase substrate. In the case of Notch, γ-
processing releases NICD that, in the nucleus, binds tran-
scription factors and activates transcription of specific
gene targets [6,7]. For APP, similar models have been sug-
gested, where AID travels to the nucleus bound to Fe65
and Tip60 to activate transcription of target genes [5]; fur-
thermore, Fe65 would also boost AID generation [8]. The
evidence that AID, Fe65 and Tip60 can all be found on the
KAI1 [9] and Neprilysin (NEP) [10] promoters supports
this model. AID gene targets that have been described so
far include KAI1 [9,11], GSK3 β [11,12], NEP [10], EGFR
[13], LRP [14] and APP itself [15], and genes involved in
cell cycle control [16] and in tumorigenesis [13]. A
genome-wide approach to AID-mediated gene transcrip-
tion has shown a possible effect of AID in regulating the
expression of proteins related to cytoskeletal organization
[17] but failed to confirm previous target genes, as have
other studies [18,19]. Given this ambiguity in results, we
have reexamined the role of AID in transcription and
apoptosis in vivo studying AID-transgenic (AIDtg) mice.
We have found that AID does not univocally regulate the
basal expression of APP, NEP, KAI1 and p53 in vivo in the
mouse brain and that the brain transcriptome of AIDtg
and littermate mice are identical. Altogether, these find-
ings suggest that a transcriptional role for AID could be
inducible. Nonetheless, toxicity tests performed on fore-
brain primary cortical neurons from AIDtg mice show that
AID has the potential to sensitize neurons to toxic stimuli,
possibly via a p53-dependent pathway [20,21].
Materials and methods
Construction of the transgenic plasmid
The cDNA sequence corresponding to human AID 50, 57
or 59 was subcloned into BamHI-XhoI sites of pHY12 vec-
tor, which bears SV40 polyA signal. A NotI-NotI fragment,
comprising the transgene, was then cloned into the pNN
vector, downstream of the 8-kb CaMKIIα promoter. The
whole plasmid was then linearized with SalI, run on aga-
rose gel, purified and injected into oocytes of FVB mice
that were than implanted in pseudo pregnant C57BL/6
mice.
Mice breeding and handling
Mice were maintained on a FVB background and handled
according to the Ethical Guidelines for Treatment of Lab-
oratory Animals of Albert Einstein College of Medicine.
The procedures were described and approved in animal
protocol number 20040707.
Mice Genotyping
Genomic DNA was extracted and purified from mice tails
with DNeasy Tissue Kit (Qiagen), according to the manu-
facturer's protocol. PCR was conducted using Taq PCR
Core Kit (Qiagen) and a Touchdown PCR protocol, start-
ing at 60°C. Primers were constructed on the pNN (fw)
and pHY (rev) vectors used for cloning, as follows: fw: 5'-
CGAGTGGCCCCTAGTTC-3', rev: 5'-CACTGCAT-
TCTAGTTGTGGTTTG-3'. Internal control primers for β-
Actin are as follows: fw: 5'-ACCCACACTGTGCCCATCTA-
3'; rev: 5'-CGGAACCGCTACTTGCC-3'. PCR products
were run on a 1.5% TBE agarose gel with 0.05% Ethidium
Bromide.
Mouse Brain Dissection
Brains were dissected from sacrificed mice using a 3-
diopter magnification lens, in ice-cold, RNase, DNase free
1× PBS (Sigma) made in DEPC double distilled water.
One hemisphere, for protein extraction, was shock frozen
in liquid nitrogen and stored at-80°C, the other hemi-
sphere was processed for RNA extraction as described.
Forebrains only were utilized.
Primary Neuronal Cultures
Culture plates were coated with 15 μg/mL Poly-L-Orni-
thine (Low Molecular Weight, Sigma) for 45 minutes at
room temperature. Poly-L-Ornithine was the aspirated
and wells were soaked with 4 μg/mL mouse Laminin (Inv-
itrogen), for 12–16 hours in a cell culture incubator at
37°C, 95% humidity and 5% CO2. Eight weeks old FVB
female mice were bred with age matched male mice for 3
days. Pregnancy was ascertained according to vaginal plug
and weight gain of the females. Females were sacrificed by
cervical dislocation, after sedation with isoflurane, at 17.5
days of gestation. Foetuses were processed separately, in
order to obtain pure transgenic cultures. Genotyping was
carried out as described, by isolating tail DNA. Forebrains
were dissected in ice cold HBSS (Invitrogen) + 0.5% w/v
D-Glucose (Sigma) and 25 mM Hepes (Invitrogen), under
a dissection microscope (Zoom 2000, Leica). Dissociation
was carried out in ice cold dissection medium plus
0.01%w/v Papain (Worthington), 0.1%w/v Dispase
(Roche) and 0.01% w/v DNase (Worthington), first by
means of sterile razor blades, then by serial pipetting with
flamed sterile glass Pasteur pipettes, and incubation at
37°C twice for 15 minutes. Cells were then spun down at
220 g for 5' at 4°C, resuspended in Neurobasal Medium
with 2% B27, 1 mM Na Pyruvate, 100 units/ml penicillin,Page 2 of 12
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rogen), filtered through a 40 μm cell strainer (Fisher),
counted and plated on coated 6 well plates at a density of
about 750.000 cells/well. Culture medium was com-
pletely replaced after 16–20 hours, and new medium
(30% of starting volume) was added every 3 days until
needed. mRNA harvest was performed at 14 and 9 DIV.
Also, at 9 DIV, neurons were treated for 3 hours with 500
μM H2O2 in culture medium devoid of Na-Pyruvate, and
for 16 hours with either 700 μM Kainic Acid (Sigma), 7
pg/μL FAS Ligand (Upstate), 1 μM Staurosporine (Sigma),
1 μM Aβ 1–42 (Anaspec) or 500 μM Glutamic Acid
(Sigma) in their regular culture medium. Also, since
replacement of conditioned culture medium with fresh
medium determines neuronal suffering in 8 h, and com-
plete death in 30 h, medium was changed 16 hours previ-
ous to cell damage and viability tests. All compounds were
resuspended, when necessary, according to the manufac-
turer's instructions, and brought to the desired concentra-
tion in sterile double distilled water. Aβ 1–42 was
solubilized in Hexafluoroisopropanol (HFIP, Sigma) to
200 μM to prevent aggregation, and stored at -80°C in
aliquots. The amount needed was then thawed, HFIP was
evaporated under the cell culture hood, and Aβ resus-
pended in sterile double distilled water to the desired con-
centration.
Immunostaining of cultured neurons and transgenic mice 
brains
Cells, plated on Poly-D-Lysine coated coverslips (24 well
plates), were washed in TBS once and fixed with 4% PFA
for 30' at room temperature (RT), washed again and per-
meabilized with 0.2% Triton X-100/TBS for 10' on ice,
and cold methanol for 5' on ice. Blocking of aspecific anti-
genic sites was performed with 10% Goat Serum/0.2%
Triton X-100/TBS for 1 hr at RT. Primary antibodies were:
anti MAP2 (Sigma, monoclonal clone HM-2, 1/500), anti
NeuN (Chemicon, monoclonal clone A60, 1/500), anti
GFAP (Abcam 7260, polyclonal 1/500). Secondary anti-
bodies were anti-mouse Alexa Fluor 350 and anti rabbit
Alexa Fluor 488, all in 5% Goat Serum/0.1% Triton X-
100/TBS for 90' at room temperature. All washes in
between and after antibodies incubations were 2 × 10'
with TBS pH7.6/0.2% Triton X-100. Coverslips were then
mouted on Superfrost Plus(+) glass slides with a glycerol
based mount and stored at 4°C, shaded from light. This
procedure was optimized in order to obtain maximum
reduction of background. Zeiss Axioskop, with fluores-
cence filters, AxioCam and Axiovision software was used
for images acquisition.
Assessment of neuronal toxicity and viability
Cell suffering was assessed by detecting LDH liberated in
the culture medium by damaged neurons treated with
toxic/pro-apoptotic stimuli (Roche), according to the
manufacturer's instructions. Cell viability was assayed by
WST1 incorporation in lively cultured neurons after treat-
ment with toxic/pro-apoptotic stimuli (Roche), according
to the manufacturer's instructions.
AID peptide detection and western blots
Frozen hemispheres were homogenized through sonica-
tion (3 × 30" cycles, with 5" pulses) in ice with HU 2–
2575 Sonifier (Branson Sonic Power) at #4 power. Buffer
is as follows: 2%SDS, 1× Roche Protease Inhibitors Com-
plete Mini-tablets, with EDTA, 5 mM Na3VO4, 50 mM
NaF, 1 mM DTT, 1 mM PMSF. Homogenates were spun
down at 49000 rpm (100000 g) on a TLA110 rotor (Beck-
man) at 4°C for 70'. Supernatants, corresponding to 1 mg
of total proteins, quantified using BIORAD Smart Spec
3000 and Protein Assay Reagent, were pre-cleared in Pro-
tein A Plus (Pierce) for 4 hours at 4°C. Lysates were then
incubated with 1 μg of rabbit C-terminal APP antibody
(Zymed) over night at 4°C. Finally, Protein A Plus
(Pierce) was added again and incubated for 4 hours at
4°C. Beads were washed, resuspended in NuPAGE LDS
Sample Buffer/β-MercaptoEthanol, boiled, and 10 μL
were loaded on a 4–12% NuPAGE gel. Proteins were then
blotted on a 0.2 μm nitrocellulose membrane (Schleicher
& Schuell), blocked in 5% milk/PBS and probed with
either rabbit anti APP C-terminal antibody (Zymed, 1/500
dilution) or with the rabbit C8 antibody (provided by
Dennis Selkoe, 1/500 dilution). Western Blots on
homogenates from AIDtg and littermate mice were car-
ried out as described previously [22]. Secondary antibody
was a goat anti rabbit-HRP (Southern Biotech, 1/3000
dilution). C8 was diluted in Superblock/PBS (Pierce),
while secondary antibody was dilute in 5% milk/PBS.
Blots were developed with SuperSignal West Pico Chemi-
luminescent Substrate (Pierce) and SuperSignal West
Dura Extended Duration Substrate (Pierce).
RT and Quantitative PCR
Each experiment was done in triplicate. Several primer
pairs were tested, prior the experiments, to check for
proper amplification and to rule out primer dimerization.
Selected primers are as follows:
-hsAID: fw: 5'-GCATCGATTCTAGAATTCG-3'; rev: 5'-
CCACCACACCATGATGAAT-3'
-hsAPP: fv: 5'-TCGGAAGTGAAGATGGATGC-3'; rev: 5'-
CCTTTGTTCGAACCCACATC-3'
-mmKAI1: fv: 5'-CCTCTTCCTCTTCAACTTGCT-3'; rev: 5'-
CGGAAATGAAGCTGTTCTTG-3'
-mmNeprilysin: fw: 5'-GGACATGAAATCACACATGG-3';
rev: 5'-AAATTATTTGCCGACTGCTG-3'Page 3 of 12
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TCTCCAGGGAGGAAGAGGAT-3'.
Mouse brain mRNA was extracted with Trizol reagent
(Invitrogen), processed and purified with RNeasy Protect
Kit (Qiagen) according to the manufacturers' protocols.
Two μg of RNA were retro transcribed to cDNA using
SuperScript III First-Strand Synthesis System for RT-PCR
kit (Invitrogen). Quantitative PCR was carried out using
Power Sybr Green PCR Master Mix on a ABI PRISM 7900
HT Sequence Detection System (Applied Biosystems)
according to the manufacturer's protocols. Data analysis
was conducted according to M. W. Pfaffl [23] and Applied
Biosystems references and protocols.
Sample preparation and hybridization for micro array 
analysis
Each experimental point was performed in triplicate.
Mouse Brains were homogenized in TRIZOL reagent (Inv-
itrogen) and extracted following the manufacturer's pro-
tocol. A further purification step with the PROTECT kit
(Qiagen) was added. cRNA was generated by using the
Affymetrix One-Cycle Target Labeling and Control Rea-
gent kit (Affymetrix Inc., Santa Clara, California, USA),
following the manufacturer's protocol. The biotinylated
cRNA was hybridized to the MOE 430 2.0 Affymetrix DNA
chips, containing over 39000 genes and open reading
frames from M. musculus Genome databases GenBank,
dbEST and RefSeq. Chips were washed and scanned on
the Affymetrix Complete GeneChip® Instrument System,
generating digitized image data files.
Micro array data analysis
DAT files were analyzed by MAS 5.0 for detection calls
(Affymetrix Inc.) and RMA for expression values. The
expression values obtained were analyzed by using Gene-
Spring GX (AgilentTechnologies). Results were filtered for
flag (presence call), then for fold change > 1.5, obtaining
a total of 5019 probe sets differentially expressed in the
samples versus the controls. Statistical analysis was ini-
tially performed using the Two-Way ANOVA using Age
and Transgene Expression as parameters to test. As Age
was the only parameter to give significant results, we next
applied a Welch T-Test on Age using as p-value cutoff
0.001, multiple testing correction Bonferroni, obtaining a
set of 380 genes statistically significant. Transgene Expres-
sion didn't give any significant result even using a p-value
cut-off 0.05.
Statistical analysis
All quantified data represent an average of at least tripli-
cate samples. Error bars represent standard errors of the
mean. Statistical significance was determined by Student's
t test and a p < 0.05 was considered significant.
Results
Generation of AID transgenic animals
To directly examine the effects of AID in vivo, and in the
brain, we generated transgenic mice expressing AID under
the control of the CaMKIIα promoter, targeting its expres-
sion to the forebrain regions (which comprise the thala-
mus, hypothalmus and the upper telencephalon) of the
postnatal mouse [24]. These areas are most relevant to
Alzheimer's pathology. Endogenous AID is very short
lived and therefore virtually undetectable [25]. We gener-
ated transgenic lines expressing either the 59- or 57-resi-
due AID peptide, which would be produced by γ-cleavage
together with either Aβ40 or Aβ42, respectively. In addi-
tion, transgenic lines expressing a "ε-cleavage" AID of 50-
residue [26,27] were also made. AID cDNAs were cloned
downstream of the 8-Kb CaMKIIα promoter and into a
plasmid containing a mini-intron and the SV40 polyade-
nylation sequence [24] (Figure 1A). The linearized plas-
mids were injected into oocytes of FVB mice that were
than implanted in pseudo pregnant C57BL/6 mice. Tail-
DNA PCR, showed that 9 out of 63 pups obtained had
integrated the AID transgenes (samples are shown in Fig-
ure 1B). More specifically, we obtained two AID59
(AID59-4.4 and -1.1), four AID57 (AID57-13.3, -5.1, -5.2
and -8.1) and three AID50 (AID50-3.4, -1.5 and 5.2)
founder mice. Germline transmission was observed for all
founders. The expression levels of the AID transgene
mRNA and protein were determined by real-time quanti-
tative PCR and Immunoprecipitation followed by West-
ern blot analysis, respectively. Total RNA and protein
lysates were isolated from the forebrain of adult AIDtg
animals. Different levels of AID mRNA and AID peptide
were found in the different transgenic mice (compare Fig-
ure 1C and 1D). Of note, AID50-1.5 and AID50-3.4 lines
expressed the highest levels of AID mRNA but no detecta-
ble AID50 protein. This data suggests that AID50 is the
more unstable AID peptide form.
All mice show, up to 24 months of age, a regular growth
pattern and mating ability, and we cannot detect any gross
deficit or behavioral abnormality among the different
AIDtg lines compared to the wild type littermates.
APP, KAI1, NEP and p53 gene expression is not altered in 
AID transgenic adult animals
To determine whether AID affects APP, KAI1, NEP and
p53 mRNA expression in vivo in the brain, RNA from the
forebrain of adult (3–8 months) AID57-5.1, AID57-13.3,
AID59-4.4, AID59-1.1, AID50-1.5, AID50-3.4, AID50-5.2
and control littermates were analyzed by real-time quan-
titative PCR. The data presented in Figure 2 show that
there is no obvious correlation between AID mRNA and
APP, KAI1, NEP and p53 levels, considering also age, sex
and AID transgene levels of expression. Overall, these data
suggest that AID is not involved in the basal expression ofPage 4 of 12
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forebrain.
AID does not regulate basal gene expression in the mouse 
brain
A role for AID in transcription cannot be nonetheless
excluded from the above evidence. AID might indeed reg-
ulate transcription of yet unidentified genes. To address
this point we took advantage of our AID tg mice. It is fore-
seeable that an AID target should be dis-regulated in the
forebrain of AID tg mice. RNA from the forebrain of
AID59-4.4, AID57-5.1, AID57-13.3 and control litterma-
tes was prepared from either 9 days or 18 days old mice.
AID50tg mice were not included in this analysis because
we could not detect expression of the AID50 peptide.
Nine day old animals were selected as further negative
controls because the transgenic cassette should be
expressed only two weeks after birth. However, we
detected expression of AID mRNA before day 18, in the 9
days old AIDtg (Figure 3). Before using these samples for
micro array analysis, the RNAs were tested for APP, KAI1,
NEP and p53 expression. Once more, we saw no clear-cut
correlation between expression of AID and that of its
putative gene targets (Figure 3, AID 57-5.1 and 13.3
Characterization of AID transgenic miceFigure 1
Characterization of AID transgenic mice. A Schematic representation of the transgenic AID constructs (fragments are 
not depicted in scale). The location of the PCR primers a and b used for genotyping is shown. B PCR of 63 pups (18 are shown 
here) revealed that 9 of them (three are shown here, number 1, 4 and 15) had integrated the AID transgene. In the same PCR 
tube, β-actin was amplified to control for genomic DNA content. Vec. represents the control PCR performed using the trans-
genic vector as a template. C Real Time PCR showing the expression levels of the AID transgene in different lines. D Immuno-
precipitation and western blot was conducted from a brain hemisphere of AIDtg and littermate (Con) mice. Mice lines that 
expressed the AID protein at the mRNA level, and had a detectable band at the western blot analysis were selected for further 
studies.Page 5 of 12
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In vivo expression of candidate AID targets is not affected by transgenic AID expression, in adult miceFigure 2
In vivo expression of candidate AID targets is not affected by transgenic AID expression, in adult mice. Real 
Time Quantitative PCR shows the relative expression of AIDtg protein, A, APP, B, NEP, C, KAI1, D, and p53, E in the forebrain 
and hippocampus of AIDtg and their littermate control mice. Values are relative to 100% value given arbitrarily to a littermate 
mouse. Experiments were conducted in triplicate loading, and the error bars represent standard deviations.
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AID is already expressed at postnatal day nine, but does not influence the expression of the candidate genesFigure 3
AID is already expressed at postnatal day nine, but does not influence the expression of the candidate genes. 
Real Time Quantitative PCR shows the relative expression of AIDtg protein A, APP, B, NEP, C, KAI1, D, and p53, E in the fore-
brain and hippocampus of AIDtg and their littermate control mice as early as 9 and 18 days post-natal. For APP, NEP, KAI1 and 
p53 expression, values are relative to 100% value given arbitrarily their day 9 and day 18 littermates. For AIDtg protein, 100% 
value was assigned to the first day 9 littermate mouse. Experiments were conducted in triplicate loading, and the error bars 
represent standard deviations.
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those genes (even their basal transcription) may still be
regulated by AID alone, without over-expression of Fe65.
Regardless, we analyzed the forebrain transcriptome of
these mice using an Affymetrix DNA chips, containing
over 39000 genes and open reading frames from M. mus-
culus Genome databases GenBank, dbEST and RefSeq. Sta-
tistical analysis performed using age and transgene
expression as parameters to test, showed that age differ-
ence was the only parameter to give significant results,
yielding a set of 380 genes that were differentially
expressed between 9 and 18 day old mice (data not
shown), indicating changes in the transcriptome during
post-natal development. Transgene expression didn't give
any significant result even using a p-value cut-off 0.05
indicating that the forebrain transcriptome was identical
in all age-matched mice analyzed. The above data argue
against a role for AID in basal transcriptional regulation.
Transgenic AID expression is detectable in fetal neurons in 
culture, does not influence the expression of target genes, 
but increases neuronal sensitivity to toxic and apoptotic 
stimuli
The finding that TgAID, under the control of our forebrain
promoter, is expressed even at postnatal day 9, has led us
to think that we could exploit the potentiality of neuronal
cultures to assess the role of AID. Neurons from embry-
onic day 17.5 fetuses, cultured for 9 days, showed detect-
able TgAID expression (Figure 4A). As for postnatal and
adult mice though, the presence of AID 57 (data not
shown for AID 59) did not seem to influence the relative
expression of our target genes (Figure 4B–E).
Since AID has been implicated in pathways leading to cell
death and apoptosis [3,12,28] we aimed to determine its
role under cellular stress conditions. We prepared neuro-
nal cultures from AID59 (and AID57, not shown) mice
and littermates. Purity of these cultures was assessed by
staining for Microtubule Associated protein 2 (MAP2),
Neuronal Nuclei (NeuN) and Glial fibrillary Acidic Pro-
tein (GFAP) (Figure 5A and 5B). MAP2 is the major micro-
tubule associated protein of brain tissue, is known to
promote microtubule assembly and to form side-arms on
microtubules. It also interacts with neurofilaments, actin,
and other elements of the cytoskeleton. It electively stains
dendrites. NeuN (or Neuronal Nuclei) reacts with most
neuronal cell types throughout the nervous system of
mice including cerebellum, cerebral cortex, hippocampus,
thalamus. Developmentally, immunoreactivity is first
observed shortly after neurons have become postmitotic.
The immunohistochemical staining is primarily localized
in the nucleus of the neurons. GFAP is a member of the
class III intermediate filament protein family. It is heavily,
and specifically, expressed in astrocytes and certain other
astroglia in the central nervous system. Antibodies to
GFAP are therefore very useful as markers of astrocytic
cells.
As shown in figure 5C, AID59 (analogous results for
AID57, not shown) positive neurons have a lower thresh-
old to cell damage induced by toxic or pro-apoptotic stim-
uli, as indicated by LDH release in culture medium. In
particular, H2O2, Kainate and Staurosporine show the
biggest differences in LDH release between AID positive
and negative cells; the biggest difference in cell viability is
seen in Kainate and Staurosporine treatments. When 1 μM
Aβ 1–42, 500 μM Glutamate and "starvation" were used
as noxious stimuli, no difference was detected between
transgenic and non-transgenic neurons (data not shown).
As expected, there was no difference in these indicators,
between AID positive and negative neurons, in non-
treated cells (not shown). In figure 5D, LDH release was
weighed with WST-1 incorporation in the same cells. It is
possible that transcription of genes involved in apoptosis,
e.g., p53 etc, may be regulated by AID under the stress or
pathological conditions.
Discussion and Conclusion
The findings that AID might regulate apoptosis and Ca++
flux were met with some skepticism. On the contrary,
hints to a transcriptional role of AID generated great
enthusiasm given the parallel with Notch signaling. Sev-
eral reports have pointed to few possible AID transcrip-
tional targets. The evidence that AID is found on the KAI1
promoter, where it is perhaps complexed to Fe65 and the
hystone acetyltransferase Tip60 [9], have supported a
direct role for AID in transcription. It can also be hypoth-
esized that AID regulates transcription indirectly and that
APP functions as a "hanger" that restrains Fe65 outside
the nucleus: APP processing would activate transcription,
as it liberates Fe65 and allows it to translocate to the
nucleus. More recent data have suggested that the APP/
Fe65 interaction promotes a "conformational matura-
tion" of Fe65 that is converted into a transcriptionally
active state [29]. However, the reported AID-dependent
changes in gene expression has been questioned [18].
Therefore, we have reexamined the role of AID in in vivo
transcription. Overexpression of AID in the mouse brain
did not affect the levels of these three putative AID gene
targets. Although these findings question the role of AID
in basal transcription of these candidate genes, it is still
possible that authentic AID targets genes have not been
yet characterized. To address this we have analyzed the
effect of AID expression on the mouse brain transcrip-
toma. The data show that the gene expression pattern of
AIDtg and littermate mice is identical, failing to identify
any other potential AID gene targets. Thus, AID might
have a transcriptional function either in a small subset of
forebrain neuronal cells, in cell types different than those
analyzed here or under specific signaling or stressful con-Page 8 of 12
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AIDtg expression in cultured fetal primary neurons does not change the relative expression of APP, NEP, KAI1 and p53Figure 4
AIDtg expression in cultured fetal primary neurons does not change the relative expression of APP, NEP, KAI1 
and p53. A AIDtg expression was confirmed by tail genotyping of fetuses (not shown) and by QPCR data on cultured neurons 
(dark bars). Expression of AID, A, APP, B, NEP, C, KAI1, D, and p53, E, is relative to the 100% value given arbitrarily to the first 
AIDtg mouse. Experiments were conducted in triplicate loading, and the error bars represent standard deviations. Cultures 
were harvested at DIV 14. Similar results were achieved from younger cultures (DIV 9, not shown) and in the AIDTg 59 line 
(not shown).
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AIDtg expression in cultured fetal primary neurons increases their sensitivity to toxic and apoptotic stimuliFigur  5
AIDtg expression in cultured fetal primary neurons increases their sensitivity to toxic and apoptotic stimuli. 
AIDTg line 59.4.4, at DIV 9. To verify the purity of the neuronal cultures, cells were stained with anti-NeuN (Blue) plus anti-
GFAP (red), A, and NeuN (Blue) plus anti-MAP2 (red), B. C Toxicity of indicated stimulus was assessed by measuring LDH 
release. D Released LDH was weighed against WST-1 uptake in the LDH/WST-1 ratio, which confirms the trend of LDH 
release. C and D Values from toxic stimuli were weighed against values from untreated cells to express the increase of the 
indicators of cell damage. Average values refer to at least 3 AIDtg and 3 littermate mice; measurements were done on 6 sepa-
rate wells of 96 well culture plate for each foetus' neurons. Similar results were obtained for AIDTg 57 line (not shown).
Molecular Neurodegeneration 2008, 3:12 http://www.molecularneurodegeneration.com/content/3/1/12ditions. Genome-wide analysis, conducted on neuronal
cells expressing inducible AID, has shown that several
genes involved in cytoskeletal dynamics can be regulated
by AID. The finding has been confirmed, by SYBR Green
real-time PCR, in brains of AD patients for 2-Actin,
IGFBP3, and TAGLN [17]. These target genes do not seem
to be regulated by AID in our model. This might be due to
two reasons. Induction of the AID transgene was allowed
for 72 hours in culture before any effect could be detected.
Our mice overexpressed AID for several days, as also evi-
dent by AID mRNA detection in cultured neurons. It is
foreseeable that any effect of AID overexpression, during
a longer period of time and in a more complex setting, as
is the living mouse brain, would probably result in a dif-
ferent expression arrangement, especially of genes
devoted to maintaining the integrity of the cell. Also, spo-
radic AD brains are a much more complex and entropic
system than ours, allowing for complex interactions
between different pathogenic entities. Thus, we cannot
exclude that a dis-regulation of these target genes may
happen later in the life of our mice or under different
stress conditions. The role of the intracellular fragment of
APP, could possibly be understood by studying its effect
under specific stress situations, e.g. under apoptotic or
oxidative stimuli, where it could play either a protective or
a detrimental role for the cell, depending on other factors
such as cell types and interaction with other proteins. This
would also explain the predisposition of some brain
regions to Alzheimer's pathology. AID has been proposed
as a possible mediator of cell death, via a reduction of the
cellular threshold to apoptosis [3]. But recent findings
have also pointed to a possible protective effect of the APP
c-terminal/Fe65 interaction, involving DNA damage
response [28]. Our data show that over-expression of AID
in cultured neuronal cells predisposes them to a higher
degree of suffering, i.e. to a lower resistance to toxic and
apoptotic stimuli. In our hands, only selective stimuli
could reveal this peculiarity, possibly because of different
threshold to cell damage for each experimental com-
pound. Recent works show a role for AID in p53 associ-
ated cell death [10]. In our model, under toxic stimuli,
AID may lower the threshold to cell death through a p53-
dependent mechanism by augmenting p53 expression.
However, further experiments are required to test this
hypothesis.
We believe that the key to understand the role of APP
processing in gene regulation lays in the complex interac-
tion of APP domains with other intra- or extra-cellular fac-
tors, possibly having a role only in certain stressful
situation or at a given "age". Further work will explore the
nature of this complex network.
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